HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...

U.S. District Judge John D. Bates granted a restraining order temporarily reversing the Trump administration’s moves to ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Preexposure prophylaxis, known as PrEP, reduces the risk of new HIV infections through sex by 99% and among injectable drug ...

Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.

Prominent health care organizations urge the Trump administration to restore important data sets on the Centers for Disease ...

HIV impacts many in the LGBTQ+ community, and those who use drugs are at increased risk. This post examines how sex contributes to this association, even for those in relationships.

HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

A federal judge appointed by a Republican President has castigated Trump administration officials — and ordered them to ...

Last week, the non-partisan not-for-profit Doctors for America (DFA) filed a lawsuit alleging the FDA, CDC, Office of Personnel Management and the Department of Health and Human Services had violated ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...